{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T10:10:10Z","timestamp":1748945410573,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This review assesses the efficacy and safety of EBRT\u2009+\u2009VBT versus VBT alone in intermediate- to high-risk endometrial cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review and meta-analysis were conducted using PubMed, EMBASE, ProQuest, Ovid, and Scopus (until February 18, 2025). Studies comparing EBRT\u2009+\u2009VBT to VBT alone were included. The primary outcome was pelvic recurrence rate, while secondary outcomes included distant recurrence, overall survival, and toxicity. Data extraction, risk of bias assessment (RoB-2, ROBINS-I), and meta-analysis (random-effects models in RevMan) were performed. Certainty of evidence was evaluated using GRADE. PROSPERO registration: CRD420250654411.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eight studies comprising 2,672 patients met inclusion criteria (1,347 received EBRT\u2009+\u2009VBT; 1,325 had VBT alone). EBRT\u2009+\u2009VBT significantly reduced pelvic recurrence (OR 0.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) but showed no difference in vaginal recurrence (OR 0.25, <jats:italic>p<\/jats:italic>\u2009=\u20090.14), distant metastasis (OR 0.78, <jats:italic>p<\/jats:italic>\u2009=\u20090.45) or overall survival (HR 0.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.29, I<jats:sup>2<\/jats:sup>\u2009=\u200972%). EBRT\u2009+\u2009VBT was associated with higher gastrointestinal, genitourinary, and hematologic toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>EBRT\u2009+\u2009VBT improves pelvic control but does not enhance survival and increases toxicity. VBT alone remains a viable option, highlighting the need for individualized treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00302-1","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:40:36Z","timestamp":1748943636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of vaginal brachytherapy versus combined pelvic external beam radiotherapy and vaginal brachytherapy in managing intermediate to high-risk endometrial cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"37","author":[{"given":"Candra Novi Ricardo","family":"Sibarani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti","family":"Salima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Adrianto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"3","key":"302_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA A Cancer J Clin"},{"issue":"1","key":"302_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.04.676","volume":"154","author":"SR Francis","year":"2019","unstructured":"Francis SR, Ager BJ, Do OA, Huang YHJ, Soisson AP, Dodson MK, et al. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154(1):38\u201344.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"302_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/GRF.0b013e318218c6d1","volume":"54","author":"MGD Carmen","year":"2011","unstructured":"Carmen MGD, Schorge JO. Recurrent Endometrial Cancer. Clin Obstet Gynecol. 2011;54(2):266\u201377.","journal-title":"Clin Obstet Gynecol"},{"key":"302_CR4","doi-asserted-by":"publisher","first-page":"612450","DOI":"10.3389\/fonc.2021.612450","volume":"11","author":"C Nero","year":"2021","unstructured":"Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Scambia G, et al. Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment. Front Oncol. 2021;11:612450.","journal-title":"Front Oncol"},{"issue":"8","key":"302_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/ijgc-2019-000317","volume":"29","author":"M Jin","year":"2019","unstructured":"Jin M, Hou X, Sun X, Zhang Y, Hu K, Zhang F. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer. Int J Gynecol Cancer. 2019;29(8):1264\u201370.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"302_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12\u201339.","journal-title":"Int J Gynecol Cancer"},{"issue":"9717","key":"302_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","volume":"375","author":"R Nout","year":"2010","unstructured":"Nout R, Smit V, Putter H, J\u00fcrgenliemk-Schulz I, Jobsen J, Lutgens L, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. The Lancet. 2010;375(9717):816\u201323.","journal-title":"The Lancet"},{"issue":"1","key":"302_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brachy.2016.04.005","volume":"16","author":"MM Harkenrider","year":"2017","unstructured":"Harkenrider MM, Block AM, Alektiar KM, Gaffney DK, Jones E, Klopp A, et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy. 2017;16(1):95\u2013108.","journal-title":"Brachytherapy"},{"issue":"6","key":"302_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/ijgc-2020-001199","volume":"30","author":"DM Narasimhulu","year":"2020","unstructured":"Narasimhulu DM, Cope A, Riaz IB, Petersen I, Cliby W, Langstraat C, et al. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2020;30(6):797\u2013805.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"302_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","volume":"33","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860\u201377.","journal-title":"Ann Oncol"},{"issue":"2","key":"302_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5114\/jcb.2018.75595","volume":"10","author":"RA Sunil","year":"2018","unstructured":"Sunil RA, Bhavsar D, Shruthi MN, Kunikullaya US, Vyas RK, Parikh A, et al. Bhavsar D, M.N. S, Kunikullaya US, R.K. V, Parikh A, et al. Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I. J Contemp Brachytherapy. 2018;10(2):105\u201314.","journal-title":"J Contemp Brachytherapy."},{"key":"302_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"M Page","year":"2021","unstructured":"Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"302_CR13","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"J Sterne","year":"2016","unstructured":"Sterne J, Hern\u00e1n M, Reeves B, Savovi\u0107 J, Berkman N, Viswanathan M. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"302_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"J Sterne","year":"2019","unstructured":"Sterne J, Savovi\u0107 J, Page M, Elbers R, Blencowe N, Boutron I. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"302_CR15","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020."},{"key":"302_CR16","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2025. Available from gradepro.org."},{"issue":"3","key":"302_CR17","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.ijrobp.2011.04.014","volume":"82","author":"B Sorbe","year":"2012","unstructured":"Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medi. Int J Rad Oncol* Biol* Phys. 2012;82(3):1249\u201355.","journal-title":"Int J Rad Oncol* Biol* Phys."},{"issue":"2","key":"302_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.31557\/APJCP.2024.25.2.485","volume":"25","author":"N Chitapanarux","year":"2024","unstructured":"Chitapanarux N, Tharavichitkul E, Kittidachanan K, Muangwong P, Chakrabandhu S, Klunklin P, et al. Retrospective Analysis of All Types of Adjuvant Radiotherapy in Endometrial Cancer: Single-Center Experiences in a Middle-Income Country. Asian Pac J Cancer Prev. 2024;25(2):485\u201394.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"20","key":"302_CR19","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.3390\/cancers14205129","volume":"14","author":"K Ren","year":"2022","unstructured":"Ren K, Zou L, Wang T, Liu Z, He J, Sun X, et al. Utilization Trend and Comparison of Different Radiotherapy Modes for Patients with Early-Stage High-Intermediate-Risk Endometrial Cancer: A Real-World, Multi-Institutional Study. Cancers. 2022;14(20):5129.","journal-title":"Cancers"},{"issue":"8","key":"302_CR20","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00432-018-2659-8","volume":"144","author":"P Hass","year":"2018","unstructured":"Hass P, Seinsch S, Eggemann H, Ignatov T, Seitz S, Ignatov A. Vaginal brachytherapy for endometrial cancer. J Cancer Res Clin Oncol. 2018;144(8):1523\u201330.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"302_CR21","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1097\/CM9.0000000000000382","volume":"132","author":"XR Hou","year":"2019","unstructured":"Hou XR, Yu L, Hu K, Zhang FQ. Outcomes of intermediate-risk to high-risk stage I endometrial cancer: 10-year clinical experiences of using in-house multi-channel applicators in a single center. Chin Med J. 2019;132(16):1935\u201341.","journal-title":"Chin Med J"},{"issue":"1","key":"302_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/s12885-021-08524-x","volume":"21","author":"W Wang","year":"2021","unstructured":"Wang W, Zou L, Wang T, Liu Z, He J, Sun X, et al. Treatment optimization of pelvic external beam radiation and\/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis. BMC Cancer. 2021;21(1):774.","journal-title":"BMC Cancer"},{"issue":"3","key":"302_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","volume":"92","author":"HM Keys","year":"2004","unstructured":"Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744\u201351.","journal-title":"Gynecol Oncol"},{"issue":"9213","key":"302_CR24","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","volume":"355","author":"CL Creutzberg","year":"2000","unstructured":"Creutzberg CL, W\u00e1rl\u00e1m-Rodenhuis CC, van de Steen-Banasik E, Beerman H, van Lent M. odenhuis CC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with. Lancet. 2000;355(9213):1404\u201311.","journal-title":"Lancet."},{"key":"302_CR25","doi-asserted-by":"publisher","unstructured":"ASTEC\/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(08)61767-5.","DOI":"10.1016\/S0140-6736(08)61767-5"},{"issue":"1","key":"302_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ygyno.2016.10.028","volume":"144","author":"V Gupta","year":"2017","unstructured":"Gupta V, McGunigal M, Prasad-Hayes M, Kalir T, Liu J. Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis. Gynecol Oncol. 2017;144(1):119\u201324.","journal-title":"Gynecol Oncol"},{"issue":"6\u20137","key":"302_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.canrad.2022.06.007","volume":"26","author":"S Espenel","year":"2022","unstructured":"Espenel S, Pointreau Y, Genestie C, Durdux C, Haie-Meder C, Chargari C. Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer. Cancer Radiother. 2022;26(6\u20137):931\u20137.","journal-title":"Cancer Radiother"},{"issue":"1","key":"302_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cam4.4423","volume":"11","author":"K Ren","year":"2021","unstructured":"Ren K, Wang W, Sun S, Hou X, Hu K, Zhang F. Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model. Cancer Med. 2021;11(1):257\u201367.","journal-title":"Cancer Med"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00302-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00302-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00302-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:40:37Z","timestamp":1748943637000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00302-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00302-1","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}